CDIOW — Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc (CDIOW) common stock listed on NASDAQ. It is led by Meeshanthini V. Dogan Ph.D., based in 311 West Superior Street, Chicago, IL, United States, 60654, with about 15 employees. Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Latest reported CDIOW revenue for 2025-09-30 was $2.9K. Net income was -$1.7M. Revenue was down 61.8% from 2025-06-30 to 2025-09-30.

Use this CDIOW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CDIOW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CDIOW SEC filings page. Lician reads the product cache first so this HTML stays unique to Cardio Diagnostics Holdings Inc even when a live quote feed is slow.